This study is in progress, not accepting new patients
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Summary
- Eligibility
- for males ages 4-16 (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Dyne Therapeutics
- ID
- NCT05524883
- Phase
- Phase 1/2 Duchenne Muscular Dystrophy Research Study
- Study Type
- Interventional
- Participants
- About 86 people participating
- Last Updated